Atossa Therapeutics Receives Approval From Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial In Canada
Portfolio Pulse from Happy Mohamed
Atossa Therapeutics, Inc. (NASDAQ:ATOS) has received approval from Health Canada to conduct its Phase 2 EVANGELINE clinical trial in Canada. The trial is a randomized non-inferiority study of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The study is expected to enroll approximately 175 patients at sites across the United States and Canada.
July 20, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics has received approval from Health Canada to conduct its Phase 2 EVANGELINE clinical trial in Canada. This could potentially increase the company's market reach and accelerate the development of its patented drug, (Z)-endoxifen.
The approval from Health Canada allows Atossa Therapeutics to expand its clinical trial to Canada, potentially increasing the number of patients for the trial and accelerating the development of its patented drug, (Z)-endoxifen. This could have a positive impact on the company's stock in the short term as it indicates progress in the company's drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100